8-K Announcements
6Material company update
Apr 29, 2026·SEC
Material company update
Mar 6, 2026·SEC
Material company update
Feb 26, 2026·SEC
PROCEPT BioRobotics Corporation(PRCT)Earnings, Financials & Key Ratios
PRCT•NASDAQ
$25.18
$1.43B mkt cap·Price updated May 6, 2026
AboutPROCEPT BioRobotics Corporation, a surgical robotics company, develops transformative solutions in urology. It develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally-invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH). The company also designs Aquablation therapy for males suffering from lower urinary tract symptoms due to BPH. As of December 31, 2021, it had an install base of 130 AquaBeam Robotic Systems worldwide comprising 78 in the United States. PROCEPT BioRobotics Corporation was incorporated in 2007 and is headquartered in Redwood City, California.Show more
- Revenue$308M+37.2%
- EBITDA-$97M-6.7%
- Net Income-$96M-4.5%
- EPS (Diluted)-1.72+1.7%
- Gross Margin63.7%+4.3%
- EBITDA Margin-31.64%+22.3%
- Operating Margin-33.71%+21.7%
- Net Margin-31.02%+23.8%
- ROE-24.89%+7.0%
- ROIC-55.69%+3.4%
- Debt/Equity0.14-29.3%
- Interest Coverage-28.96-38.9%
PRCT Key Insights
PROCEPT BioRobotics Corporation (PRCT) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Strong 5Y sales CAGR of 109.0%
✗Weaknesses
- ✗Profits declining 12.5% over 5 years
- ✗Negative free cash flow
- ✗Trading more than 30% below 52-week high
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
PRCT Price & Volume
PROCEPT BioRobotics Corporation (PRCT) stock price & volume — 10-year historical chart
Loading chart...
PRCT Growth Metrics
PROCEPT BioRobotics Corporation (PRCT) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years109.04%
3 Years60.14%
TTM29.26%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-13.61%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-7.06%
Return on Capital
10 Years-38.35%
5 Years-26.44%
3 Years-26.67%
Last Year-22.5%
PRCT Recent Earnings
PROCEPT BioRobotics Corporation (PRCT) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 8/12 qtrs (67%)●Beat Revenue 6/12 qtrs (50%)
Q2 2026Latest
Apr 29, 2026EPS
$0.56
Est $0.55
-1.8%
Revenue
$83M
Est $81M
+3.2%
Q1 2026
Feb 25, 2026EPS
$0.53
Est $0.32
-65.6%
Revenue
$76M
Est $94M
-18.5%
Q4 2025
Nov 4, 2025EPS
$0.38
Est $0.41
+7.3%
Revenue
$83M
Est $94M
-11.1%
Q3 2025
Aug 6, 2025EPS
$0.35
Est $0.41
+14.6%
Revenue
$79M
Est $84M
-6.1%
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | Apr 29, 2026 | $0.56vs $0.55-1.8% | $83Mvs $81M+3.2% |
| Q1 2026 | Feb 25, 2026 | $0.53vs $0.32-65.6% | $76Mvs $94M-18.5% |
| Q4 2025 | Nov 4, 2025 | $0.38vs $0.41+7.3% | $83Mvs $94M-11.1% |
| Q3 2025 | Aug 6, 2025 | $0.35vs $0.41+14.6% | $79Mvs $84M-6.1% |
Based on last 12 quarters of dataView full earnings history →
PRCT Peer Comparison
PROCEPT BioRobotics Corporation (PRCT) competitors in Surgical tools, endoscopy, and robotics — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 ISRG | 160.32B | 451.38 | 57.35 | 20.51% | 28.15% | 16.89% | 1.55% | 0.02 |
 NVCR | 1.81B | 15.88 | -13.02 | 8.28% | -25.66% | -50.82% | 0.85 | |
 NTRA | 28.44B | 206.77 | -135.14 | 56.75% | -14.61% | -24.69% | 0.24% | 0.16 |
 TNDM | 1.33B | 19.42 | -6.39 | 7.93% | -20.17% | -141.98% | 2.86 | |
 NVS | 277.63B | 145.50 | 20.24 | 5.97% | 24.14% | 31.42% | 6.37% | 0.80 |
 BSX | 83.2B | 55.98 | 28.86 | 19.87% | 14.4% | 12.4% | 4.4% | 0.51 |
 EW | 47.8B | 82.91 | 45.31 | 11.55% | 17.64% | 10.35% | 2.79% | 0.07 |
 ANGO | 455.65M | 10.96 | -13.20 | -3.76% | -9.02% | -15.71% |
Compare PRCT vs Peers
PROCEPT BioRobotics Corporation (PRCT) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
PRCT Income Statement
PROCEPT BioRobotics Corporation (PRCT) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 6.17M | 7.72M | 34.47M | 75.01M | 136.19M | 224.5M | 308.05M | 322.02M |
| Revenue Growth % | - | 25.09% | 346.72% | 117.6% | 81.55% | 64.84% | 37.22% | 29.26% |
| Cost of Goods Sold | 8.05M | 8.97M | 18.61M | 37.93M | 65.14M | 87.4M | 111.83M | 119.22M |
| COGS % of Revenue | 130.56% | 116.26% | 53.98% | 50.56% | 47.83% | 38.93% | 36.3% | - |
| Gross Profit | -1.89M▲ 0% | -1.25M▲ 33.4% | 15.87M▲ 1364.1% | 37.09M▲ 133.8% | 71.05M▲ 91.6% | 137.1M▲ 93.0% | 196.23M▲ 43.1% | 202.81M▲ 0% |
| Gross Margin % | -30.56% | -16.26% | 46.02% | 49.44% | 52.17% | 61.07% | 63.7% | 62.98% |
| Gross Profit Growth % | - | 33.42% | 1364.14% | 133.75% | 91.58% | 92.96% | 43.13% | - |
| Operating Expenses | 41.66M | 46.55M | 70.03M | 117.81M | 180.22M | 233.71M | 300.08M | 311.83M |
| OpEx % of Revenue | 675.39% | 603.17% | 203.14% | 157.05% | 132.33% | 104.1% | 97.41% | - |
| Selling, General & Admin | 28.52M | 30.27M | 51.04M | 88.83M | 131.77M | 171.41M | 228.81M | 238.7M |
| SG&A % of Revenue | 462.28% | 392.28% | 148.05% | 118.42% | 96.76% | 76.35% | 74.28% | - |
| Research & Development | 13.15M | 16.27M | 18.99M | 28.98M | 48.45M | 62.3M | 71.28M | 73.13M |
| R&D % of Revenue | 213.11% | 210.9% | 55.1% | 38.63% | 35.57% | 27.75% | 23.14% | - |
| Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 |
| Operating Income | -43.55M▲ 0% | -47.8M▼ 9.8% | -54.16M▼ 13.3% | -80.72M▼ 49.0% | -109.17M▼ 35.2% | -96.61M▲ 11.5% | -103.86M▼ 7.5% | -109.03M▲ 0% |
| Operating Margin % | -705.95% | -619.44% | -157.12% | -107.61% | -80.16% | -43.04% | -33.71% | -33.86% |
| Operating Income Growth % | - | -9.76% | -13.31% | -49.04% | -35.24% | 11.5% | -7.5% | - |
| EBITDA | -42.06M | -44.94M | -50.84M | -77.88M | -105.36M | -91.38M | -97.47M | -102.38M |
| EBITDA Margin % | -681.73% | -582.38% | -147.48% | -103.82% | -77.36% | -40.7% | -31.64% | -31.79% |
| EBITDA Growth % | - | -6.86% | -13.12% | -53.19% | -35.28% | 13.27% | -6.66% | -12.65% |
| D&A (Non-Cash Add-back) | 1.49M | 2.86M | 3.32M | 2.84M | 3.81M | 5.23M | 6.39M | 6.65M |
| EBIT | -41.25M | -47.76M | -54.04M | -81.97M | -101.9M | -87.23M | -103.86M | -109.03M |
| Net Interest Income | 425K | -5.08M | -5.73M | -2.69M | 3.56M | 6.71M | 8.63M | -3.53M |
| Interest Income | 1.15M | 184K | 76K | 2.5M | 7.55M | 10.89M | 12.22M | 0 |
| Interest Expense | 724K | 5.26M | 5.81M | 5.18M | 4M | 4.18M | 3.59M | 3.53M |
| Other Income/Expense | 1.57M | -5.22M | -5.69M | -6.43M | 3.27M | 5.2M | 8.48M | 6.75M |
| Pretax Income | -41.98M▲ 0% | -53.02M▼ 26.3% | -59.85M▼ 12.9% | -87.15M▼ 45.6% | -105.9M▼ 21.5% | -91.41M▲ 13.7% | -95.38M▼ 4.3% | -102.28M▲ 0% |
| Pretax Margin % | -680.42% | -687.04% | -173.62% | -116.18% | -77.76% | -40.72% | -30.96% | -31.76% |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 190K | 190K |
| Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% | -0.2% | -0.19% |
| Net Income | -41.98M▲ 0% | -53.02M▼ 26.3% | -59.85M▼ 12.9% | -87.15M▼ 45.6% | -105.9M▼ 21.5% | -91.41M▲ 13.7% | -95.57M▼ 4.5% | -102.47M▲ 0% |
| Net Margin % | -680.42% | -687.04% | -173.62% | -116.18% | -77.76% | -40.72% | -31.02% | -31.82% |
| Net Income Growth % | - | -26.31% | -12.89% | -45.61% | -21.51% | 13.68% | -4.55% | -13.61% |
| Net Income (Continuing) | -41.98M | -53.02M | -59.85M | -87.15M | -105.9M | -91.41M | -95.57M | -102.47M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -1.25▲ 0% | -1.51▼ 20.8% | -1.37▲ 9.3% | -1.96▼ 43.1% | -2.24▼ 14.3% | -1.75▲ 21.9% | -1.72▲ 1.7% | -1.81▲ 0% |
| EPS Growth % | - | -20.8% | 9.27% | -43.07% | -14.29% | 21.88% | 1.71% | -7.06% |
| EPS (Basic) | -1.25 | -1.51 | -1.37 | -1.96 | -2.24 | -1.75 | -1.72 | - |
| Diluted Shares Outstanding | 33.59M | 35.14M | 43.7M | 44.4M | 47.26M | 52.13M | 55.54M | 56.51M |
| Basic Shares Outstanding | 33.59M | 35.14M | 43.7M | 44.4M | 47.26M | 52.13M | 55.54M | 56.51M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - |
PRCT Balance Sheet
PROCEPT BioRobotics Corporation (PRCT) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 50.36M | 109.9M | 326.17M | 272.63M | 350.57M | 481.84M | 450.38M | 428.03M |
| Cash & Short-Term Investments | 42.02M | 100.13M | 304.32M | 222.64M | 257.22M | 333.73M | 286.5M | 245.64M |
| Cash Only | 42.02M | 100.13M | 304.32M | 222.64M | 257.22M | 333.73M | 286.5M | 245.64M |
| Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accounts Receivable | 1.1M | 1.55M | 4.46M | 15.27M | 48.38M | 83.5M | 83.53M | 96.39M |
| Days Sales Outstanding | 65.02 | 73.26 | 47.26 | 74.31 | 129.65 | 135.75 | 98.97 | 97.83 |
| Inventory | 6.69M | 7.48M | 13.15M | 28.54M | 39.76M | 56.17M | 70.69M | 77.54M |
| Days Inventory Outstanding | 303 | 304.18 | 257.88 | 274.68 | 222.76 | 234.57 | 230.74 | 215.83 |
| Other Current Assets | 0 | 0 | 3.41M | 6.17M | 5.21M | 8.45M | 9.65M | 8.47M |
| Total Non-Current Assets | 11.64M | 16.07M | 10.85M | 36.7M | 54.15M | 52.17M | 57.7M | 59.03M |
| Property, Plant & Equipment | 8.27M | 12.91M | 8.32M | 32.14M | 48.99M | 45.65M | 47.94M | 48.9M |
| Fixed Asset Turnover | 0.75x | 0.60x | 4.14x | 2.33x | 2.78x | 4.92x | 6.43x | 6.72x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 2.29M | 2.02M | 1.75M | 1.48M | 1.2M | 932K | 709K | 640K |
| Long-Term Investments | 691K | 777K | 777K | 3.04M | 3.04M | 3.04M | 0 | 12.06M |
| Other Non-Current Assets | 378K | 356K | 0 | 51K | 919K | 2.56M | 9.06M | 22.9M |
| Total Assets | 61.99M▲ 0% | 125.97M▲ 103.2% | 337.02M▲ 167.5% | 309.33M▼ 8.2% | 404.72M▲ 30.8% | 534.02M▲ 31.9% | 508.08M▼ 4.9% | 487.06M▲ 0% |
| Asset Turnover | 0.10x | 0.06x | 0.10x | 0.24x | 0.34x | 0.42x | 0.61x | 0.64x |
| Asset Growth % | - | 103.2% | 167.54% | -8.22% | 30.84% | 31.95% | -4.86% | 62.7% |
| Total Current Liabilities | 6.79M | 14.53M | 16.24M | 35.29M | 45.93M | 53.13M | 65.8M | 63.64M |
| Accounts Payable | 1.44M | 1.24M | 2.03M | 9.39M | 13.5M | 10.03M | 17.29M | 18.85M |
| Days Payables Outstanding | 65.44 | 50.45 | 39.8 | 90.37 | 75.64 | 41.9 | 56.42 | 45.19 |
| Short-Term Debt | 0 | 6.26M | 2.1M | 2.13M | 1.68M | 1.91M | 0 | 0 |
| Deferred Revenue (Current) | 106K | 233K | 1.02M | 2.85M | 5.66M | 9.56M | 13.05M | 47.3M |
| Other Current Liabilities | 2.9M | 2.15M | 4.61M | 7.47M | 8.2M | 10.09M | 35.46M | 31.08M |
| Current Ratio | 7.42x | 7.57x | 20.08x | 7.73x | 7.63x | 9.07x | 6.85x | 6.85x |
| Quick Ratio | 6.43x | 7.05x | 19.27x | 6.92x | 6.77x | 8.01x | 5.77x | 5.77x |
| Cash Conversion Cycle | 302.59 | 327 | 265.35 | 258.61 | 276.77 | 328.43 | 273.3 | 268.47 |
| Total Non-Current Liabilities | 25.97M | 50.48M | 53.69M | 76.97M | 78.04M | 78.66M | 76.42M | 75.76M |
| Long-Term Debt | 23.22M | 44.41M | 50M | 51.21M | 51.34M | 51.47M | 51.62M | 51.66M |
| Capital Lease Obligations | 0 | 4.1M | 1.99M | 23.98M | 26.18M | 26.87M | 0 | 51.01M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 2.75M | 1.98M | 1.7M | 1.78M | 517K | 324K | 24.8M | 49.7M |
| Total Liabilities | 32.76M | 65.01M | 69.93M | 112.26M | 123.97M | 131.8M | 142.21M | 139.4M |
| Total Debt | 23.22M | 54.76M | 54.1M | 77.32M | 79.2M | 80.25M | 51.62M | 51.66M |
| Net Debt | -18.8M | -45.37M | -250.22M | -145.32M | -178.02M | -253.47M | -234.89M | -193.98M |
| Debt / Equity | 0.79x | 0.90x | 0.20x | 0.39x | 0.28x | 0.20x | 0.14x | 0.14x |
| Debt / EBITDA | - | - | - | - | - | - | - | -0.50x |
| Net Debt / EBITDA | - | - | - | - | - | - | - | 1.89x |
| Interest Coverage | -56.98x | -9.08x | -9.30x | -15.82x | -25.51x | -20.85x | -28.96x | -30.92x |
| Total Equity | 29.23M▲ 0% | 60.96M▲ 108.5% | 267.09M▲ 338.1% | 197.07M▼ 26.2% | 280.75M▲ 42.5% | 402.22M▲ 43.3% | 365.87M▼ 9.0% | 347.67M▲ 0% |
| Equity Growth % | - | 108.55% | 338.14% | -26.22% | 42.46% | 43.27% | -9.04% | 91.18% |
| Book Value per Share | 0.87 | 1.73 | 6.11 | 4.44 | 5.94 | 7.72 | 6.59 | 6.15 |
| Total Shareholders' Equity | 29.23M | 60.96M | 267.09M | 197.07M | 280.75M | 402.22M | 365.87M | 347.67M |
| Common Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Retained Earnings | -148.65M | -201.67M | -261.52M | -348.68M | -454.57M | -545.99M | -641.56M | -673.2M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 4K | -14K | -54K | -6K | 84K | 114K | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
PRCT Cash Flow Statement
PROCEPT BioRobotics Corporation (PRCT) cash flow — operating, investing & free cash flow history
| Line item | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -43.82M | -48.34M | -57.33M | -80.38M | -108M | -99.21M | -48.98M | -48.98M |
| Operating CF Margin % | -710.29% | -626.45% | -166.32% | -107.16% | -79.3% | -44.19% | -15.9% | - |
| Operating CF Growth % | - | -10.33% | -18.6% | -40.2% | -34.36% | 8.14% | 50.63% | 12.69% |
| Net Income | -41.98M | -53.02M | -59.85M | -87.15M | -105.9M | -91.41M | -95.57M | -102.47M |
| Depreciation & Amortization | 1.49M | 2.86M | 3.32M | 2.84M | 3.81M | 5.23M | 6.39M | 6.65M |
| Stock-Based Compensation | 1.99M | 2.17M | 3.8M | 10.34M | 19.13M | 31.84M | 47.6M | 50.57M |
| Deferred Taxes | 0 | 0 | 451K | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | -1.8M | 126K | -345K | 5.08M | 1.11M | 2.45M | 433K | -21.03M |
| Working Capital Changes | -3.53M | -483K | -4.71M | -11.49M | -26.16M | -47.33M | -7.84M | -3.85M |
| Change in Receivables | 522K | -511K | -2.91M | -10.81M | -33.1M | -35.96M | -898K | -18.14M |
| Change in Inventory | -5.07M | -3.1M | -6.12M | -15.25M | -9.75M | -17.23M | -14.5M | -7.94M |
| Change in Payables | -260K | -205K | 812K | 3.96M | 5.79M | -2.15M | 6.65M | 5.22M |
| Cash from Investing | 43.15M | -233K | -592K | -2.65M | -25.21M | -4.41M | -9.36M | -10.43M |
| Capital Expenditures | -7.61M | -233K | -592K | -2.65M | -25.21M | -4.41M | -9.36M | -10.43M |
| CapEx % of Revenue | 123.37% | 3.02% | 1.72% | 3.54% | 18.51% | 1.96% | 3.04% | - |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - |
| Other Investing | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash from Financing | 26.53M | 106.77M | 262.12M | 3.61M | 167.79M | 180.13M | 11.19M | 10.12M |
| Debt Issued (Net) | 24.53M | 24.68M | 0 | 1.2M | 0 | 0 | 0 | 0 |
| Equity Issued (Net) | 0 | 76.49M | 257.07M | 0 | 161.71M | 164.52M | 11.19M | 4.44M |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 1.99M | 5.6M | 5.04M | 2.42M | 6.09M | 15.6M | 0 | 5.68M |
| Net Change in Cash | 25.86M▲ 0% | 58.2M▲ 125.0% | 204.19M▲ 250.9% | -79.42M▼ 138.9% | 34.59M▲ 143.5% | 76.5M▲ 121.2% | -47.22M▼ 161.7% | -70.56M▲ 0% |
| Free Cash Flow | -51.43M▲ 0% | -48.58M▲ 5.5% | -57.93M▼ 19.2% | -83.03M▼ 43.3% | -133.21M▼ 60.4% | -103.62M▲ 22.2% | -58.34M▲ 43.7% | -80.57M▲ 0% |
| FCF Margin % | -833.67% | -629.47% | -168.03% | -110.69% | -97.81% | -46.16% | -18.94% | -25.02% |
| FCF Growth % | - | 5.55% | -19.25% | -43.35% | -60.43% | 22.21% | 43.7% | 8.66% |
| FCF per Share | -1.53 | -1.38 | -1.33 | -1.87 | -2.82 | -1.99 | -1.05 | -1.05 |
| FCF Conversion (FCF/Net Income) | 1.04x | 0.91x | 0.96x | 0.92x | 1.02x | 1.09x | 0.51x | 0.79x |
| Interest Paid | 397K | 3.97M | 0 | 4.29M | 0 | 0 | 0 | 1.75M |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
PRCT Key Ratios
PROCEPT BioRobotics Corporation (PRCT) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -117.57% | -36.49% | -37.55% | -44.32% | -26.77% | -24.89% | -27.7% |
| Return on Invested Capital (ROIC) | -275.51% | -250.27% | -176.45% | -106% | -57.63% | -55.69% | -55.69% |
| Gross Margin | -16.26% | 46.02% | 49.44% | 52.17% | 61.07% | 63.7% | 62.98% |
| Net Margin | -687.04% | -173.62% | -116.18% | -77.76% | -40.72% | -31.02% | -31.82% |
| Debt / Equity | 0.90x | 0.20x | 0.39x | 0.28x | 0.20x | 0.14x | 0.14x |
| Interest Coverage | -9.08x | -9.30x | -15.82x | -25.51x | -20.85x | -28.96x | -30.92x |
| FCF Conversion | 0.91x | 0.96x | 0.92x | 1.02x | 1.09x | 0.51x | 0.79x |
| Revenue Growth | 25.09% | 346.72% | 117.6% | 81.55% | 64.84% | 37.22% | 29.26% |
PRCT SEC Filings & Documents
PROCEPT BioRobotics Corporation (PRCT) SEC filings — annual & quarterly reports (10-K, 10-Q)
PRCT Frequently Asked Questions
PROCEPT BioRobotics Corporation (PRCT) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
PROCEPT BioRobotics Corporation (PRCT) reported $322.0M in revenue for fiscal year 2025. This represents a 5120% increase from $6.2M in 2019.
PROCEPT BioRobotics Corporation (PRCT) grew revenue by 37.2% over the past year. This is strong growth.
PROCEPT BioRobotics Corporation (PRCT) reported a net loss of $102.5M for fiscal year 2025.
Dividend & Returns
PROCEPT BioRobotics Corporation (PRCT) has a return on equity (ROE) of -24.9%. Negative ROE indicates the company is unprofitable.
PROCEPT BioRobotics Corporation (PRCT) had negative free cash flow of $80.6M in fiscal year 2025, likely due to heavy capital investments.
Explore More PRCT
PROCEPT BioRobotics Corporation (PRCT) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates